Lassen L F, Hirsch B E, Kamerer D B
Department of Otolaryngology-Head and Neck Surgery, Naval Medical Center, Portsmouth, Virginia 23708, USA.
Am J Otol. 1996 Jul;17(4):577-80.
Nimodipine is a highly lipophilic, centrally acting calcium channel blocker. It is similar in action to flunarizine, which has been studied for use in the medical treatment of Menière's disease.
Nimodipine was offered to patients with Menière's disease for whom first-line medical management failed (dietary restrictions and diuretics or vestibular suppressants).
Our preliminary clinical experience using nimodipine in 12 patients with Menière's disease from December 1992 until March 1995 resulted in successful control of vertigo and hearing improvement or stabilization in seven (58%) of 12 patients. When hearing stabilization was not considered, eight (67%) patients had vertigo satisfactorily controlled (AAOO class A, B, or C). The four (33%) patients whose vertigo symptoms persisted despite treatment with nimodipine (AAOO class D) were surgically treated with successful vertigo control. Nimodipine was discontinued in one class D patient because of gastrointestinal intolerance.
Nimodipine provides an alternative successful means for medical management of Menière's disease.
尼莫地平是一种高度亲脂性的中枢性钙通道阻滞剂。其作用与氟桂利嗪相似，后者已被研究用于梅尼埃病的药物治疗。
将尼莫地平提供给一线药物治疗（饮食限制、利尿剂或前庭抑制剂）失败的梅尼埃病患者。
我们从1992年12月至1995年3月对12例梅尼埃病患者使用尼莫地平的初步临床经验显示，12例患者中有7例（58%）眩晕得到成功控制，听力改善或稳定。若不考虑听力稳定情况，8例（67%）患者的眩晕得到满意控制（美国耳鼻咽喉头颈外科学会（AAOO）分级为A、B或C级）。4例（33%）尽管接受尼莫地平治疗但眩晕症状仍持续的患者（AAOO分级为D级）接受了手术治疗，眩晕得到成功控制。1例D级患者因胃肠道不耐受停用了尼莫地平。
尼莫地平为梅尼埃病的药物治疗提供了一种成功的替代方法。
